Analyst Richard Close of Canaccord Genuity maintained a Buy rating on Omada Health, Inc., with a price target of $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Richard Close has given his Buy rating due to a combination of factors that highlight Omada Health, Inc.’s strong performance and future potential. The company has shown significant revenue momentum, achieving a notable milestone with its first quarter of positive adjusted EBITDA. This financial achievement, along with an increase in annual guidance that suggests a 49% revenue growth at the midpoint, underscores the company’s robust financial health.
Additionally, Omada’s strategic initiatives, such as the expansion of its GLP-1 programs and successful partnerships, notably with CVS, have contributed to its accelerated growth. The company’s ability to attract new clients and expand existing relationships, alongside its innovative approach to managing GLP-1 prescriptions, positions it well in the evolving healthcare landscape. These factors, combined with a conservative yet optimistic outlook for future quarters, support Close’s Buy rating for Omada Health, Inc.
In another report released today, Barclays also maintained a Buy rating on the stock with a $29.00 price target.